<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058044</url>
  </required_header>
  <id_info>
    <org_study_id>AU792</org_study_id>
    <secondary_id>RCB 2009-A00244-53</secondary_id>
    <nct_id>NCT01058044</nct_id>
  </id_info>
  <brief_title>Adherence to Oral Anticancer Treatment Using Electronic Monitoring System</brief_title>
  <official_title>A Pilot Study of Adherence to Oral Anticancer Treatment Using Electronic Monitoring System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe adherence to 3 oral anticancer treatment: i) a
      chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or
      sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor.
      Moreover, this study is aimed at evaluating the feasibility to use a &quot; Medication Event
      Monitoring System &quot; (MEMS®) in order to assess adherence of an oral anticancer treatment
      delivered by dispensary pharmacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation of adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor.</measure>
    <time_frame>everey visit during 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of liberal nurse satisfaction</measure>
    <time_frame>inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resort to healthcare system (oncologist, doctor, nurse, hospital pharmacy, dispensary pharmacy)</measure>
    <time_frame>during 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drug interaction</measure>
    <time_frame>during 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>adherence assessment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>evaluation of adherence using MEMS</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of adherence to 3 oral anticancer treatment using a &quot; Medication Event Monitoring System &quot;</intervention_name>
    <description>Evaluation of adherence using a &quot; Medication Event Monitoring System &quot; (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy</description>
    <arm_group_label>adherence assessment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  histologically proven malignant tumor

          -  documented decision of treatment with i) a chemotherapeutic regimen with capecitabine
             (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase
             inhibitor, iii) or an non-steroidal aromatase inhibitor

          -  ambulatory treated subject

          -  Subject who accept to use MEMS monitors to automatically compile their drug dosing
             histories

          -  Written informed consent

        Exclusion Criteria:

          -  any severe concomitant wich makes it undesirable for the patient to participate in the
             study or which would jeopardize adherence with trial protocol

          -  patient who does not agreed to participate the program
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2010</study_first_submitted>
  <study_first_submitted_qc>January 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2010</study_first_posted>
  <last_update_submitted>August 8, 2012</last_update_submitted>
  <last_update_submitted_qc>August 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer, Sunitinib, capecitabine, anastrozole, letrozole</keyword>
  <keyword>adherence, anticancer treatment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

